In addition to direct cytotoxicity against malignant cells, XPO1 inhibitors may modulate the immediate tumor immune microenvironment to promote T-cell fitness and reduce T-cell exhaustion, as demonstrated in preclinical melanoma and acute lymphoblastic leukemia (ALL) models (9, 10). The gene discussed is XPO1; the disease is neoplasm.